Mineralys Therapeutics, Inc. (MLYS) — Financial statements
Income statement, balance sheet, and cash flow for Mineralys Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 132↓21.7% | 169↑139.6% | 70↑168.0% | 26↑61.0% | 16 | |
| General & Administrative Expenses | 39↑62.0% | 24↑66.6% | 14↑173.4% | 5↑116.3% | 2 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 39↑62.0% | 24↑66.6% | 14↑173.4% | 5↑116.3% | 2 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 171↓11.3% | 192↑127.3% | 85↑168.9% | 31↑68.1% | 19 | |
| Total Costs & Expenses | 171↓11.3% | 192↑127.3% | 85↑168.9% | 31↑68.1% | 19 | |
| Operating Results | ||||||
| Operating Income | -171↑11.3% | -192↓127.3% | -85↓168.9% | -31↓68.1% | -19 | |
| Depreciation & Amortization | 0.06↑37.2% | 0.04 | 0.00 | 0.00 | 0.00 | |
| EBITDA | -171↑11.3% | -192↓127.2% | -85↓168.9% | -31↓62.4% | -19 | |
| EBIT | -171↑11.3% | -192↓127.3% | -85↓168.9% | -31↓62.4% | -19 | |
| Interest & Other Income | ||||||
| Net Interest Income | 16↑9.4% | 15↑14.4% | 13 | 0.00↑100.0% | -0.03 | |
| Interest Income | 16↑9.4% | 15↑14.4% | 13↑661.1% | 2 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 2↑6107.4% | 0.03 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.66 | |
| Other Income / Expenses | 16↑9.3% | 15↑14.4% | 13↑659.5% | 2↑346.0% | -0.68 | |
| Income Before Tax | -155↑13.0% | -178↓147.3% | -72↓141.3% | -30↓53.5% | -19 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -155↑13.0% | -178↓147.3% | -72↓141.3% | -30↓53.5% | -19 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -155↑13.0% | -178↓147.3% | -72↓141.3% | -30↓53.5% | -19 | |
| Bottom-Line Net Income | -155↑13.0% | -178↓147.3% | -72↓141.3% | -30↓53.5% | -19 | |
| EPS (Basic) | -2.29↑37.4% | -3.66↓83.9% | -1.99↑65.5% | -5.77↓48.3% | -3.89 | |
| EPS (Diluted) | -2.29↑37.4% | -3.66↓83.9% | -1.99↑65.5% | -5.77↓48.3% | -3.89 | |
| Weighted Average Shares | 68↑39.4% | 49↑34.1% | 36↑600.4% | 5↑3.7% | 5 | |
| Weighted Average Diluted Shares | 68↑39.4% | 49↑34.1% | 36↑600.3% | 5↑3.7% | 5 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.